Publications by authors named "G Ehninger"

Claim this Profile
H
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Katja Sockel, Christoph Röllig, Anke Mütherig, Martina Crysandt, Sven Zukunft, Gerhard Ehninger

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Anne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, Katja Sockel, Rebekka Wehner, Gerhard Ehninger

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Gerhard Ehninger

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux, Gerhard Ehninger

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.
Sebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, Claudia D Baldus, Uwe Platzbecker, Gerhard Ehninger

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis